TICKERNERD
Menu
EVHEVHHealthcare · Health Information Services

EVH Stock Forecast: Evolent Health, Inc. Price Predictions for 2026-2027

Last close, 17 Sept 2026
$3.67
−1.87% on the day

The 15 Wall Street analysts covering Evolent Health, Inc. hold a median 12-month price target of $6 — +63.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 17 Sept 2026 — in the upper half.

Market cap
$422.8M
Ticker Nerd rank
59 / 100
Median analyst target
$6.00
Analysts covering
15
Revenue$652.5M+46.9% y/y
Operating income−$9.6M
Net income−$28.4M
Free cash flow−$16.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.0%
1M
−16.8%
YTD
−8.3%
1Y
−57.0%
From 52W high
−61.8%
From 52W low
+69.1%
$2.17
$9.61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EVH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evolent Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Issuance
92
Value
68
Revisions
67
Size
56
Growth
33
Quality
32
Volatility
21
Momentum
9

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EVH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EVH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26EVHHigh $8.00Median $6.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
12 Buy3 Hold0 Sell
Low $3.00Median $6.00High $8.00

The green dot is the last close — the median target sits +63.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
18 Aug 2026JP MorganMaintainsOverweight$5.00 → $6.00
17 Aug 2026TD CowenMaintainsBuy$5.00 → $6.00
12 Aug 2026Truist SecuritiesMaintainsHold$7.00 → $6.00
11 Aug 2026CitigroupUpgradeBuy$6.75 → $6.00
10 Aug 2026Canaccord GenuityMaintainsBuy$7.00 → $6.00
10 Aug 2026Canaccord GenuityMaintainsBuy—
28 July 2026TD CowenMaintainsBuy—
28 July 2026TD CowenMaintainsBuy$8.00 → $5.00
23 July 2026CitigroupDowngradeNeutral—
23 July 2026CitigroupDowngradeNeutral$5.50 → $6.75
21 July 2026Canaccord GenuityMaintainsBuy$6.00 → $7.00
21 July 2026Canaccord GenuityMaintainsBuy—
30 June 2026Truist SecuritiesDowngradeHold—
30 June 2026Truist SecuritiesDowngradeHold$7.00
12 June 2026Truist SecuritiesMaintainsBuy—
15 May 2026CitigroupMaintainsBuy—
12 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026NeedhamMaintainsBuy—
2 Mar 2026OppenheimerMaintainsOutperform—
26 Feb 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EVH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, Evolent Health, Inc. returned −57.0% against +17.0% for the S&P 500, dividends included.

EVH vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26EVHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EVH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.7%
Analysts raising
8
Analysts cutting
1
Fundamentals

Evolent Health, Inc. (EVH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
0.2×

Cheaper than 93% of US stocks

Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
20.9×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
46.9%

Higher than 85% of US stocks

Earnings growth (YoY)
—
Gross margin
12.4%

Higher than 11% of US stocks

Operating margin
−1.3%

Higher than 31% of US stocks

Net margin
−24.1%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−67.0%

Higher than 18% of US stocks

Return on assets
−0.8%

Higher than 40% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Evolent Health, Inc. (EVH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Evolent Health, Inc. has a market value of $422.8M and an enterprise value of $1.3B.

  • Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 46.9% year on year.

  • Net income over the same four quarters: −$505.0M, a −24.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.57.

  • Free cash flow in the twelve months to 30 June 2026: $24.3M.

  • Evolent Health, Inc. spent $1.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 112.7M.

  • Trailing P/E: −0.7×; forward P/E: 9.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Evolent Health, Inc. employs 4,200 people — $499K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

EVH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
EVHEvolent Health, Inc.$422.8M
59
CARLCarlsmed, Inc.$418.4M
29
SLPSimulations Plus, Inc.$372.9M
90
NRCNRC Health$470.3M
93
CTEVClaritev Corp.$522.7M
65
WEAVWeave Communications, Inc.$586.4M
84
PHRPhreesia, Inc.$619.8M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Evolent Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EVH news & analysis

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Seeking Alpha · 13 Aug 2026positive

A Seeking Alpha article gives Evolent Health a contrarian Buy rating, highlighting that while the company carries ~$967 million in long-term debt and persistent GAAP losses, management projects over 25% revenue growth and adjusted EBITDA of at least $150 million by 2027.

Why it matters — EVH watchers would care because the article suggests the company's deeply distressed valuation (~0.2x forward sales) could improve if management succeeds in reducing leverage and achieving its growth and profitability targets.

Evolent Health Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Evolent Health reported second-quarter revenue of $653 million, up 31% from the first quarter, and adjusted EBITDA of $28 million, up 27% sequentially. The company cited the May launch of its Highmark partnership and continued growth in its Performance Suite business as drivers.

Why it matters — The Q2 results show sequential growth in revenue and adjusted EBITDA tied to the new Highmark partnership and Performance Suite momentum, which are key areas for EVH watchers.

Evolent Health, Inc. (EVH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Evolent Health, Inc. held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The transcript covers the company's second-quarter 2026 financial results and related discussion.

Why it matters — EVH watchers would care because the earnings call transcript provides direct insight into the company's quarterly performance and management commentary.

Compared to Estimates, Evolent Health (EVH) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 6 Aug 2026neutral

Zacks reported on Evolent Health's (EVH) Q2 2026 earnings, noting that while top- and bottom-line numbers show how the business performed in the quarter ended June 2026, it is also worth examining how key metrics compare to Wall Street estimates and year-ago values.

Why it matters — EVH watchers would care because comparing key metrics to analyst estimates and prior-year figures reveals how closely the quarter's performance tracked expectations.

Evolent Health (EVH) Tops Q2 Earnings and Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

Evolent Health reported quarterly earnings of $0.02 per share for Q2, beating the Zacks Consensus Estimate of a $0.01 per share loss and improving from a $0.10 per share loss a year earlier. The company also topped revenue estimates for the quarter.

Why it matters — The results mark a year-over-year improvement and a beat on consensus estimates, offering EVH watchers a snapshot of the company's ongoing financial performance.

FAQ

Frequently asked questions about EVH stock

What is the EVH stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Evolent Health, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EVH stock a buy right now?

Of the 15 analysts covering Evolent Health, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evolent Health, Inc. 59 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EVH?

As at 17 Sept 2026, Evolent Health, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will EVH stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +63.5% from the last close, and Ticker Nerd's factor model ranks Evolent Health, Inc. 59 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EVH stock forecast for 2030?

No analyst covering Evolent Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8 over the next 12 months.

How has EVH stock performed over the past year?

Evolent Health, Inc. returned -57.0% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evolent Health, Inc. do?

Evolent Health Inc Class A Common Stock represents ownership in Evolent Health, a healthcare services company focused on improving care for people with complex medical conditions. The company provides specialty care management, population health solutions, and administrative services that help health plans, physicians, and care organizations coordinate treatment and manage costs.

What is the latest news on EVH?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming". A Seeking Alpha article gives Evolent Health a contrarian Buy rating, highlighting that while the company carries ~$967 million in long-term debt and persistent GAAP losses, management projects over 25% revenue growth and adjusted EBITDA of at least $150 million by 2027.

Company

About Evolent Health, Inc.

Evolent Health Inc Class A Common Stock represents ownership in Evolent Health, a healthcare services company focused on improving care for people with complex medical conditions. The company provides specialty care management, population health solutions, and administrative services that help health plans, physicians, and care organizations coordinate treatment and manage costs. Its offerings include oncology and cardiology care management, musculoskeletal support, pharmacy benefit and risk management, analytics, reporting, and technology-enabled workflow tools. Evolent also supports value-based care programs by helping clients align care delivery with outcomes and efficiency. Headquartered in Arlington, Virginia, Evolent Health serves the U.S. healthcare market through products and services designed to simplify care operations and improve clinical coordination across multiple stages of the patient journey.

CEO Mr. Seth Barrie Blackley · 4,200 employees · United States · https://www.evolent.com